Polish public radio runs a story framing Ozempic as something other than a weight loss drug. Only the title is available, so the full argument is at the source.
Recap by typeshit. Full story at www.polskieradio.pl.
The Darling Ingredients unit says the supplement ingredient concentrates over ten neurosupportive peptides, with clinical trials planned to start in December.
The plastic surgeon weighs in on semaglutide and other GLP-1 drugs as more patients of every age turn to them for major weight loss.
Toby notes Lilly posted $22.97 billion in Q2 2026 revenue, up 46% in a year, driven by one molecule sold under two brand names.
Traders Union looks at whether Novo Nordisk shares can hold their gains, pointing to the Wegovy pill approval and recent trial data.
LifeMD's chief medical officer says the pill is the same drug with stricter daily rules and possibly more stomach side effects, and cheaper mainly for cash payers.
The CHMP backed orforglipron for weight management and type 2 diabetes. Trial users lost about 5 to 11% of body weight over 72 weeks, depending on dose.
Loading…